Showing results (301-310 of 310) with videos related to
Sort By:
Pageof 31
You have reached the last page of results.This site can display upto 310 results.
Liver Cancer|May 12, 2021
What Can Be Done to Solve the Unmet Clinical Need of Hepatocellular Carcinoma Patients following Lenvatinib Failure?Atsushi Hiraoka, Takashi Kumada, Toshifumi Tada, et al.Scientific Reports|July 15, 2021
Impact of modified albumin-bilirubin grade on survival in patients with HCC who received lenvatinibToshifumi Tada, Takashi Kumada, Atsushi Hiraoka, et al.Journal of Gastroenterology and Hepatology|November 10, 2020
Clinical importance of muscle volume in lenvatinib treatment for hepatocellular carcinoma: Analysis adjusted with inverse probability weightingAtsushi Hiraoka, Takashi Kumada, Kazuya Kariyama, et al.Scientific Reports|August 18, 2021
Efficacy of lenvatinib for unresectable hepatocellular carcinoma based on background liver disease etiology: multi-center retrospective studyAtsushi Hiraoka, Takashi Kumada, Toshifumi Tada, et al.Hepatology Research : the Official Journal of the Japan Society of Hepatology|December 3, 2020
Analysis of efficacy of lenvatinib treatment in highly advanced hepatocellular carcinoma with tumor thrombus in the main trunk of the portal vein or tumor with more than 50% liver occupation: A multicenter analysisMakoto Chuma, Haruki Uojima, Atsushi Hiraoka, et al.Cancer Medicine|June 6, 2022
Does first-line treatment have prognostic impact for unresectable HCC?-Atezolizumab plus bevacizumab versus lenvatinibAtsushi Hiraoka, Takashi Kumada, Toshifumi Tada, et al.Oncology|August 8, 2023
Comparison between Atezolizumab Plus Bevacizumab and Lenvatinib for Hepatocellular Carcinoma in Patients with Child-Pugh Class B in Real-World Clinical SettingsHideko Ohama, Atsushi Hiraoka, Toshifumi Tada, et al.Hepatology Research : the Official Journal of the Japan Society of Hepatology|April 10, 2021
Therapeutic efficacy of lenvatinib as third-line treatment after regorafenib for unresectable hepatocellular carcinoma progressionAtsushi Hiraoka, Takashi Kumada, Takeshi Hatanaka, et al.Scientific Reports|January 3, 2025
Geriatric nutritional risk index and newly developed scoring system as prognosis prediction for unresectable hepatocellular carcinoma patients treated with lenvatinibHideko Ohama, Atsushi Hiraoka, Toshifumi Tada, et al.Liver International : Official Journal of the International Association for the Study of the Liver|July 12, 2021
Adverse events as potential predictive factors of activity in patients with advanced hepatocellular carcinoma treated with lenvatinibIlario Giovanni Rapposelli, Toshifumi Tada, Shigeo Shimose, et al.Pageof 31